Investigational drug · Phase 2
ALTO-300
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Major Depressive Disorder.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "ALTO-300"
First trial start
2023
Jun 8, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ALTO-300", any sponsor or status.
Conditions studied
As listed on its trial records.
- Major Depressive Disorder
Approved drugs for the same conditions: Depression (major depressive disorder) · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "ALTO-300" as an intervention, largest first.
- Study of ALTO-300 in MDDPivotal-lookingRecruiting
Alto NeuroscienceIndustry
NCT05922878 · 325 participants (planned) · Start Jun 8, 2023 · Primary completion Dec 2026
Drug: ALTO-300; Placebo · For: Major Depressive Disorder
Sites: Phoenix, Arizona; Yuma, Arizona; Rogers, Arkansas · 75 sites in all
Alto NeuroscienceIndustry
NCT05157945 · 148 participants · Start Feb 3, 2022 · Primary completion Apr 26, 2023
Drug: ALTO-300 PO Tablet · For: Major Depressive Disorder
Sites: Atlanta, Georgia; Jackson, Mississippi; New York, New York · 4 sites in all
- ALTO-300 in DepressionCompleted
Alto NeuroscienceIndustry
NCT05118750 · 91 participants · Start Dec 13, 2021 · Primary completion May 5, 2023
Drug: ALTO-300 oral (PO) tablet · For: Major Depressive Disorder
Sites: Culver City, California; Sacramento, California; Santee, California · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Next-Generation Pharmacotherapies for Unipolar Mood Disorders: A Leading Article on Phase II/III Drug Development Across Diverse Mechanisms.
King A, Hardy M, Rhee TG, et al. · CNS Drugs 2026
- Novel approaches in depression treatment: from rapid-acting antidepressants to personalized interventions.
Guidetti C, Fava M, Papakostas GI · Mol Psychiatry 2026
Also in development for Major Depressive Disorder
- BrenipatideLY3537031Phase 313 trials
Eli Lilly · Alcohol Use Disorder, Irritable Bowel Syndrome, Depressive Disorder, Major
- AzetukalnerXEN1101Phase 39 trials
Xenon Pharmaceuticals Inc. · Focal Onset Seizures, Major Depressive Disorder, Bipolar Disorder
- SEP-363856UlotarontPhase 37 trials
Otsuka · Generalized Anxiety Disorder, Schizophrenia, Major Depressive Disorder
- BHV-7000Phase 36 trials
Biohaven Therapeutics Ltd. · Focal Epilepsy, Major Depressive Disorder, Bipolar Disorder
- NBI-1065845TAK-653, OsavampatorPhase 35 trials
Neurocrine Biosciences · Major Depressive Disorder
- CYM-53093Navacaprant, NMRA-335140Phase 34 trials
Neumora Therapeutics, Inc. · Major Depressive Disorder, Major Depressive Episode Associated With Bipolar II Disorder
- DT120MM120, lysergide tartratePhase 34 trials
Definium Therapeutics US, Inc. · Generalized Anxiety Disorder, Major Depressive Disorder
- PsilocybinCOMP360Phase 34 trials
COMPASS Pathways · Treatment Resistant Depression, Major Depressive Disorder, Anorexia Nervosa
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.